Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

477.36 +4.27 (+0.90%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

75 76 Next >

Should You Buy Vertex Before Feb. 12? ↗

February 10, 2026

Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12

Via The Motley Fool

Topics Intellectual Property

Provident Dumps 490,000 MapleBear Shares Worth $18 Million ↗

February 09, 2026

Maplebear Inc. connects North American households with personal shoppers through its technology-driven grocery delivery platform.

Via The Motley Fool

Topics Regulatory Compliance

Should You Buy Vertex Pharmaceuticals Before Feb. 12? ↗

February 09, 2026

The next 12 months will be important for the drugmaker.

Via The Motley Fool

The Bond Market Is Flashing a Clear Warning About the Fed: 3 Stocks to Buy ↗

February 08, 2026

The bond market is speaking more loudly than the stock market about the likely direction of the Federal Reserve.

Via The Motley Fool

Topics Bonds Economy Government

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Growth and Breakout Opportunity ↗

February 02, 2026

Via Chartmill

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Value Case ↗

January 29, 2026

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment Candidate ↗

January 13, 2026

Via Chartmill

2 Top Healthcare Stocks to Buy in February ↗

February 07, 2026

There's a bright future ahead for both, but it's important to be patient.

Via The Motley Fool

Topics World Trade

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 Market-Beating Stocks Worth Investigating

February 04, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the...

Via StockStory

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Compelling Value Stock Candidate ↗

January 01, 2026

Via Chartmill

Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals ↗

January 29, 2026

The biotech could be on the verge of expanding its lineup and entering a new era of growth.

Via The Motley Fool

1 Healthcare Stock to Consider Right Now and 2 We Brush Off

January 28, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Via StockStory

Topics Stocks

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

January 23, 2026

Issued on behalf of Avant Technologies Inc.

From Equity Insider

Via GlobeNewswire

Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)

January 21, 2026

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its...

Via StockStory

Topics Artificial Intelligence

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

January 20, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

January 19, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Vertex Pharmaceuticals...

Via StockStory

Topics Artificial Intelligence

My Forever Portfolio: 5 Stocks I Don't Plan on Ever Selling ↗

January 19, 2026

These stocks are definitely keepers.

Via The Motley Fool

Topics Artificial Intelligence

3 Profitable Stocks with Open Questions

January 15, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

January 14, 2026

Plenty of growth lies ahead for these top healthcare companies.

Via The Motley Fool

Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS

January 13, 2026

On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari...

Via MarketMinute

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 11, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

The Best Stocks to Invest $50,000 in Right Now ↗

January 11, 2026

These stocks should be good bets in the new year.

Via The Motley Fool

Topics Artificial Intelligence

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

Via MarketMinute

Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 ↗

January 09, 2026

It could be another tough year for the once-soaring drugmaker.

Via The Motley Fool

Topics Intellectual Property

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Via PredictStreet

Topics Economy Initial Public Offering Intellectual Property

Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies

January 07, 2026

Check out the companies making headlines yesterday:

Via StockStory

Topics Artificial Intelligence

Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

January 06, 2026

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and issued a $548 price...

Via StockStory

My 10 Top Stocks to Buy to Start the New Year Off Right ↗

January 05, 2026

Investing in a few of these players could increase the diversification of your portfolio.

Via The Motley Fool

Topics Artificial Intelligence

BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations

January 02, 2026

As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional...

Via MarketMinute

Topics Artificial Intelligence Economy

< Previous 1 2 3 4 5 6 7 8 9

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.